MDLinx August 30, 2024
Key Takeaways
Germany’s BioNTech is trialing a new cancer vaccine called BNT116. It is an mRNA vaccine designed to treat advanced non-small cell lung cancer.
The vaccine is currently being evaluated alone and in combination with a monoclonal antibody medication in phase 2 trials. The trial will be conducted in seven countries and will establish safety profile and dosing.
Experts think the vaccine candidate is promising but much more information is needed.
A new cancer vaccine candidate—BNT116—could be a source of hope for patients with advanced non-small cell lung cancer (NSCLC).
BNT116 is designed not only to recognize and...
Today's Sponsors
Today's Sponsor